Skip to content

Design preview by DWE Consult — “ELYSEA Life Sciences Group” is a concept name for design exploration, not the official website. Learn more

Menu

ELYSEA Life Sciences Group

Advancing vision. Together.

We develop innovative therapeutics to help maintain vision and improve ocular health.

Explore our pipeline Investor hub

NCX 470 · NO-donating bimatoprost

For glaucoma and ocular hypertension

  1. Two positive Phase 3 trials (Mont Blanc, Denali) (opens nicox.com in a new tab)

    Completed

  2. U.S. NDA submitted by Kowa (PDF, opens nicox.com in a new tab)

  3. China NDA submitted by Ocumension (PDF, opens nicox.com in a new tab)

  4. China NDA accepted for review (PDF, opens nicox.com in a new tab)

  5. FDA target action date (PDUFA) (PDF, opens nicox.com in a new tab)

Status as of Oct 21, 2026

Full pipeline

4 programs in our portfolio

15+ countries where VYZULTA® is marketed

5 partners worldwide

Latest news

All news

Shareholder Letter · September 2026

Read (PDF) (PDF, opens nicox.com in a new tab)